参考文献/References:
[1] FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Cancer incidence and mortality patterns in Europe:estimates for 40 countries and 25 major cancers in 2018[J].Eur J Cancer,2018,103:356-387.
[2] CHIEN J,POOLE E.Ovarian cancer prevention,screening and early detection:report from the 11th biennial ovarian cancer research symposium[J].Int J Gynecol Cancer,2017,27(9S Suppl 5):S20-S22.
[3] ROJAS V,HIRSHFIELD K M,GANESAN S,et al.Molecular characterization of epithelial ovarian cancer:implications for diagnosis and treatment[J].Int J Mol Sci,2016,17(12):2113.
[4] GARZON S,LAGANà A S,CASARIN J,et al.Secondary and tertiary ovarian cancer recurrence:what is the best management[J].Gland Surg,2020,9(4):1118-1129.
[5] LHEUREUX S,OAKNIN A,GARG S,et al.EVOLVE:a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression[J].Clin Cancer Res,2020,26(16):4206-4215.
[6] 时佳琪,刘超,张艳桥,等.甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析[J].中国肿瘤临床,2018,45(4):191-195.
SHI J Q,LIU C,ZHANG Y J,et al.Analysis of clinical adverse reactions of apatinib for the treatment of malignant tumors[J].Chin Oncol Clin,2018,45(4):191-195.
[7] LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34 (13):1448-1454.
[8] GREGORY J,DIOGUARDI BURGIO M,CORRIAS G,et al.Evaluation of liver tumour response by imaging[J].JHEP Rep,2020,2(3):100100.
[9] SMITH TL,SARTO G,HELOW K,et al.Impact of change from CTCAE Version 3 to CTCAE Version 4 on urologic toxicity scores in prostate cancer-international journal of Radiation Oncology Biology Physics[J].Int J Radiat Oncol Biol Phys,2014,90(1):S419.
[10] MOR V,LALIBERTE L,MORRIS J N,et al.The karnofsky performance status scale.An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[11] GRUNEWALD T,LEDERMANN J A.Targeted therapies for ovarian cancer[J].Best Pract Res Clin Obstet Gynaecol,2017,41:139-152.
[12] SUN H,XIAO M,LIU S,et al.Use of apatinib combined with pemetrexed for advanced ovarian cancer:a case report[J].Medicine (Baltimore),2018,97 (27):e11036
[13] GARZON S,LAGAN A S,CASARIN J,et al.Secondary and tertiary ovarian cancer recurrence:what is the best management?[J].Gland Surg,2020,9(4):1118-1129.
[14] LEE Y J,LEE I H,KIM Y J,et al.Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy[J].PLoS One,2018,13(9):e0203366.
[15] URUSKI P,SEPETOWSKA A,KONIECZNA C,et al.Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro[J].Cell Mol Biol Lett,2021,26(1):44.
[16] WANG S,YAO Y,YAO M,et al.Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathway[J].Biochem Biophys Res Commun,2018,503(3):1605-1609.
[17] HE M,ZHU J,YU N,et al.The superior antitumor effect of self-assembled paclitaxel nanofilaments for lung cancer cells[J].Curr Drug Deliv,2019,16(2):171-178.
[18] ROVILLO G,RAVELLI A,POLOM K,et al.Apatinib:a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].Cancer Lett,2016,372(2):189-191.
[19] 王婷,马惠文,王东林,等.甲磺酸阿帕替尼片单药三线治疗VEGFR-2高表达晚期非鳞NSCLC患者的近期疗效和安全性体会[J].实用肿瘤杂志,2018,33(5):410-415.
WANG T,MA H W,WANG D L,et al.Short-term efficacy and safety of apatinib mesylate tablets in third-line monotherapy for advanced non-squamous NSCLC with high VEGFR-2 expression[J].J Pract Oncol,2018,33(5):410-415.
[20] DING J,CHENG XY,LIU S,et al.Apatinib exerts anti-tumour effects on ovarian cancer cells[J].Gynecol Oncol,2019,153(1):165-174.
[21] ZHANG J,LI A,JIANG Q,et al.Efficacy and safety of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer:a real world study[J].Drug Des Devel Ther,2019,13:3913-3918.
[22] 褚超男,黄琪.阿帕替尼治疗复发性卵巢癌的疗效及安全性评价[J].中国新药杂志,2020,29(3):299-302.
CHU C N,HANG Q.Efficacy and safety of apatinib in the chemotherapy of recurrent platinum resistant ovarian cance[J].Chin J New Drugs,2020,29(3):299-302.
[23] MIAO M,DENG G,LUO S,et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
相似文献/References:
[1]叶林华,袁苏徐.紫杉醇联合卡培他滨治疗晚期胃癌疗效观察[J].新乡医学院学报,2011,28(01):102.
[2]张少华,刘凯歌,郑建云,等.上皮性卵巢癌中癌胚抗原相关细胞黏附分子1和CD105的表达[J].新乡医学院学报,2012,29(11):834.
[3]沈慧敏,梁武凤,杨 君,等.人附睾蛋白4、溶血磷脂酸和糖类抗原125联合检测在上皮性卵巢癌诊断中的价值[J].新乡医学院学报,2014,31(11):922.[doi:10.7683/xxyxyxb.2014.11.016]
[4]丁 锋,张清会.厄洛替尼联合紫杉醇和顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报,2018,35(6):513.[doi:10.7683/xxyxyxb.2018.06.016]
DING Feng,ZHANG Qing-hui.Effect of erlotinib combined with paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer[J].Journal of Xinxiang Medical University,2018,35(4):513.[doi:10.7683/xxyxyxb.2018.06.016]
[5]常 伟,丁 敏,周建华,等.曲妥珠单抗联合紫杉醇治疗人表皮生长因子受体-2过表达转移性乳腺癌的疗效和安全性评价[J].新乡医学院学报,2018,35(6):517.[doi:10.7683/xxyxyxb.2018.06.017]
CHANG Wei,DING Min,ZHOU Jian-hua,et al.Efficacy and safety of trastuzumab combined with paclitaxel for treatment of human epidermal growth factor receptor-2 overexpressing metastatic breast cancer patients[J].Journal of Xinxiang Medical University,2018,35(4):517.[doi:10.7683/xxyxyxb.2018.06.017]
[6]李小峰,孙新宇,张 慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]